Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study).


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 04 12 2018
revised: 20 03 2019
accepted: 22 03 2019
pubmed: 3 5 2019
medline: 1 2 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

Growth differentiation factor-15 (GDF-15) has appeared as a promising biomarker with strong predictive abilities in acute coronary syndrome (ACS). However, studies are solely based on single measurements in the acute phase of an ACS event. The way GDF-15 patterns in post-ACS patients behave on the long term is largely unknown. We conducted a nested case-control study within our multicenter, prospective, observational biomarker study (BIOMArCS) of 844 ACS patients. Following an index ACS event, high-frequency blood sampling was performed during 1-year of follow-up. GDF-15 was determined batchwise by electrochemiluminescence immunoassays in 37 cases with a recurrent event during 1-year follow-up, and in 74 event-free controls. Cases and controls had a mean ± standard deviation age of 66.9 ± 11.3 years and 81% were men. From 30 days onwards, patients showed stable levels, which were on average 333 (95% confidence interval 68 to 647) pg/mL higher in cases than controls (1704 vs 1371 pg/mL; p value 0.013). Additionally, in the post 30-day period, GDF-15 showed low within-individual variability in both cases and controls. In conclusion, post-ACS patients experiencing a recurrent event had stable and systematically higher GDF-15 levels during 30-day to 1-year follow-up than their event-free counterparts with otherwise similar clinical characteristics. Thus, postdischarge blood sampling might be used throughout the course of 1 year to improve prognostication, whereas, in view of the low within-individual variation, the number of repeated sampling moments might be limited.

Identifiants

pubmed: 31047655
pii: S0002-9149(19)30415-1
doi: 10.1016/j.amjcard.2019.03.049
pii:
doi:

Substances chimiques

Biomarkers 0
GDF15 protein, human 0
Growth Differentiation Factor 15 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-13

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Nermina Buljubasic (N)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Maxime M Vroegindewey (MM)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Rohit M Oemrawsingh (RM)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Folkert W Asselbergs (FW)

Division Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.

Etienne Cramer (E)

Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Anho Liem (A)

Department of Cardiology, Sint Franciscus Gasthuis, Rotterdam, the Netherlands.

Pim van der Harst (P)

Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands.

Arthur Maas (A)

Department of Cardiology, Gelre Hospitals, Zutphen, the Netherlands.

Eelko Ronner (E)

Department of Cardiology, Reinier de Graaf, Delft, the Netherlands.

Carl Schotborgh (C)

Department of Cardiology, HagaZiekenhuis, The Hague, the Netherlands.

Alexander J Wardeh (AJ)

Department of Cardiology, Haaglanden Medical Center, The Hague, the Netherlands.

K Martijn Akkerhuis (KM)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Eric Boersma (E)

Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: h.boersma@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH